{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:09:59Z","timestamp":1793639399676,"version":"4.5.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41584-024-01093-w","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:02:12Z","timestamp":1710136932000},"page":"232-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["TYK2: an emerging therapeutic target in rheumatic disease"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric","family":"Morand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semarthrit.2020.09.016","volume":"51","author":"DL Conn","year":"2021","unstructured":"Conn, D. L. The story behind the use of glucocorticoids in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 51, 15\u201319 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233\u2013247 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan, D. P., Pope, J. E., Gotlib, J. & Harrison, C. N. Current and future status of JAK inhibitors. Lancet 398, 803\u2013816 (2021).","journal-title":"Lancet"},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41584-018-0155-9","volume":"15","author":"JJ O\u2019Shea","year":"2019","unstructured":"O\u2019Shea, J. J. & Gadina, M. Selective Janus kinase inhibitors come of age. Nat. Rev. Rheumatol. 15, 74\u201375 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/art.41906","volume":"73","author":"C Liu","year":"2021","unstructured":"Liu, C., Kieltyka, J., Fleischmann, R., Gadina, M. & O\u2019Shea, J. J. A decade of JAK inhibitors: what have we learned and what may be the future? Arthritis Rheumatol. 73, 2166\u20132178 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1093_CR6","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nri1226","volume":"3","author":"K Shuai","year":"2003","unstructured":"Shuai, K. & Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3, 900\u2013911 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.2741\/3908","volume":"16","author":"B Strobl","year":"2011","unstructured":"Strobl, B., Stoiber, D., Sexl, V. & Mueller, M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. 16, 3214\u20133232 (2011).","journal-title":"Front. Biosci."},{"key":"1093_CR8","doi-asserted-by":"crossref","unstructured":"Burke, J. R. et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci. Transl. Med. 11 (2019).","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1002\/eji.201646519","volume":"46","author":"S Fuchs","year":"2016","unstructured":"Fuchs, S. et al. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur. J. Immunol. 46, 2639\u20132649 (2016).","journal-title":"Eur. J. Immunol."},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng, M. W. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719\u2013729 (2015).","journal-title":"Nat. Med."},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang, K., Oak, A. S. W. & Elewski, B. E. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am. J. Clin. Dermatol. 22, 173\u2013192 (2021).","journal-title":"Am. J. Clin. Dermatol."},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh, J. A. et al. 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 71, 5\u201332 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann. Rheum. Dis. 79, 700\u2013712 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter, A. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 80, 1029\u20131072 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s41927-022-00287-7","volume":"6","author":"S Sarabia","year":"2022","unstructured":"Sarabia, S., Ranjith, B., Koppikar, S. & Wijeratne, D. T. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol. 6, 71 (2022).","journal-title":"BMC Rheumatol."},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie, R. A. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, e208\u2013e219 (2019).","journal-title":"Lancet Rheumatol."},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian, K. C. et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 75, 253\u2013265 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2017-212794","volume":"77","author":"N Hagberg","year":"2018","unstructured":"Hagberg, N. et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-\u03b3 production in T cells from patients with SLE. Ann. Rheum. Dis. 77, 1070\u20131077 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrg3502","volume":"14","author":"M Parkes","year":"2013","unstructured":"Parkes, M., Cortes, A., van Heel, D. A. & Brown, M. A. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 14, 661\u2013673 (2013).","journal-title":"Nat. Rev. Genet."},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1086\/428480","volume":"76","author":"S Sigurdsson","year":"2005","unstructured":"Sigurdsson, S. et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528\u2013537 (2005).","journal-title":"Am. J. Hum. Genet."},{"key":"1093_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002341","volume":"7","author":"DS Cunninghame Graham","year":"2011","unstructured":"Cunninghame Graham, D. S. et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 7, e1002341 (2011).","journal-title":"PLoS Genet."},{"key":"1093_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00403-018-1858-0","volume":"310","author":"Q Yin","year":"2018","unstructured":"Yin, Q. et al. Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis. Arch. Dermatol. Res. 310, 711\u2013728 (2018).","journal-title":"Arch. Dermatol. Res."},{"key":"1093_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122271","volume":"10","author":"D Diogo","year":"2015","unstructured":"Diogo, D. et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS One 10, e0122271 (2015).","journal-title":"PLoS One"},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1136\/annrheumdis-2015-208154","volume":"75","author":"E Lopez-Isac","year":"2016","unstructured":"Lopez-Isac, E. et al. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. Ann. Rheum. Dis. 75, 1521\u20131526 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/hmg\/ddr522","volume":"21","author":"L Bossini-Castillo","year":"2012","unstructured":"Bossini-Castillo, L. et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum. Mol. Genet. 21, 926\u2013933 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"1093_CR27","doi-asserted-by":"publisher","first-page":"584414","DOI":"10.3389\/fimmu.2021.584414","volume":"12","author":"L Hu","year":"2021","unstructured":"Hu, L. et al. Interleukin-22 from type 3 innate lymphoid cells aggravates lupus nephritis by promoting macrophage infiltration in lupus-prone mice. Front. Immunol. 12, 584414 (2021).","journal-title":"Front. Immunol."},{"key":"1093_CR28","first-page":"400","volume":"37","author":"X Yang","year":"2018","unstructured":"Yang, X. et al. Increased interleukin-22 levels in lupus nephritis and its associated with disease severity: a study in both patients and lupus-like mice model. Clin. Exp. Rheumatol. 37, 400\u2013407 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1093_CR29","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/annrheumdis-2014-205440","volume":"73","author":"M Jani","year":"2014","unstructured":"Jani, M. et al. Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. Ann. Rheum. Dis. 73, 1750\u20131752 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1093_CR30","doi-asserted-by":"publisher","first-page":"685280","DOI":"10.3389\/fgene.2021.685280","volume":"12","author":"D Hromadova","year":"2021","unstructured":"Hromadova, D., Elewaut, D., Inman, R. D., Strobl, B. & Gracey, E. From science to success? targeting tyrosine kinase 2 in spondyloarthritis and related chronic inflammatory diseases. Front. Genet. 12, 685280 (2021).","journal-title":"Front. Genet."},{"key":"1093_CR31","unstructured":"Takeda. Takeda announces positive results in phase 2b study of investigational TAK-279, an oral, once-daily TYK2 inhibitor, in people with moderate-to-severe plaque psoriasis [press release]. Takeda.com https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/takeda-announces-positive-results-in-phase-2b-study-of-investigational-tak-279\/ (2023)."},{"key":"1093_CR32","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp, K. et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N. Engl. J. Med. 379, 1313\u20131321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1093_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong, A. W. et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J. Am. Acad. Dermatol. 88, 29\u201339 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1093_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober, B. et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial. J. Am. Acad. Dermatol. 88, 40\u201351 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1093_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease, P. J. et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann. Rheum. Dis. 81, 815\u2013822 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1093_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson, D. T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheumatol. 38, 727\u2013735 (1995).","journal-title":"Arthritis Rheumatol."},{"key":"1093_CR37","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie, R. A. et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheumatol. 61, 1143\u20131151 (2009).","journal-title":"Arthritis Rheumatol."},{"key":"1093_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242\u2013252 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1093_CR39","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2665-9913(21)00119-3","volume":"3","author":"K Connelly","year":"2021","unstructured":"Connelly, K., Golder, V., Kandane-Rathnayake, R. & Morand, E. F. Clinician-reported outcome measures in lupus trials: a problem worth solving. Lancet Rheumatol. 3, e595\u2013e603 (2021).","journal-title":"Lancet Rheumatol."},{"key":"1093_CR40","doi-asserted-by":"publisher","unstructured":"Wu, C. et al. Pharmacodynamic changes in SLE relevant gene expression induced by deucravacitinib in patients enrolled in the phase 2. Arthritis Rheumatol. 75 https:\/\/doi.org\/10.1002\/art.42700 (2023).","DOI":"10.1002\/art.42700"},{"key":"1093_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace, D. J. et al. Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. 73, 183\u2013190 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1093_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","volume":"147","author":"R Klein","year":"2011","unstructured":"Klein, R. et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch. Dermatol. 147, 203\u2013208 (2011).","journal-title":"Arch. Dermatol."},{"key":"1093_CR43","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder, V. et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 1, e95\u2013e102 (2019).","journal-title":"Lancet Rheumatol."},{"key":"1093_CR44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri, M. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401, 1011\u20131019 (2023).","journal-title":"Lancet"},{"key":"1093_CR45","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand, E. F. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401, 1001\u20131010 (2023).","journal-title":"Lancet"},{"key":"1093_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000424","volume":"7","author":"T Dorner","year":"2020","unstructured":"Dorner, T. et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci. Med. 7, e000424 (2020).","journal-title":"Lupus Sci. Med."},{"key":"1093_CR47","doi-asserted-by":"publisher","first-page":"110420","DOI":"10.1016\/j.celrep.2022.110420","volume":"38","author":"A Vogel","year":"2022","unstructured":"Vogel, A. et al. JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction. Cell Rep. 38, 110420 (2022).","journal-title":"Cell Rep."},{"key":"1093_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073980","volume":"383","author":"EF Morand","year":"2023","unstructured":"Morand, E. F., Fernandez-Ruiz, R., Blazer, A. & Niewold, T. B. Advances in the management of systemic lupus erythematosus. BMJ 383, e073980 (2023).","journal-title":"BMJ"},{"key":"1093_CR49","unstructured":"ClinicalTrials.gov, United States National Library of Medicine. Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis, https:\/\/clinicaltrials.gov\/study\/NCT05478499 (2023)."},{"key":"1093_CR50","unstructured":"ClinicalTrials.gov. United States National Library of Medicine. A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1), https:\/\/clinicaltrials.gov\/study\/NCT05617677 (2024)."},{"key":"1093_CR51","unstructured":"ClinicalTrials.gov. United States National Library of Medicine. A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Na\u00efve to Biologic Disease-modifying Anti-rheumatic Drugs, https:\/\/clinicaltrials.gov\/study\/NCT04908202 (2024)."},{"key":"1093_CR52","unstructured":"ClinicalTrials.gov, United States National Library of Medicine. A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and\/ or Subacute Cutaneous Lupus Erythematosus (DLE\/SCLE), https:\/\/clinicaltrials.gov\/study\/NCT04857034 (2024)."},{"key":"1093_CR53","unstructured":"ClinicalTrials.gov, United States National Library of Medicine. A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata https:\/\/clinicaltrials.gov\/study\/NCT05556265 (2024)."},{"key":"1093_CR54","unstructured":"ClinicalTrials.gov, United States National Library of Medicine. A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn\u2019s Disease or Ulcerative Colitis. https:\/\/clinicaltrials.gov\/study\/NCT04877990 (2023)."},{"key":"1093_CR55","unstructured":"ClinicalTrials.gov, United States National Library of Medicine. A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis. https:\/\/clinicaltrials.gov\/study\/NCT04613518 (2023)."},{"key":"1093_CR56","doi-asserted-by":"publisher","first-page":"i091","DOI":"10.1093\/ecco-jcc\/jjab232.081","volume":"16","author":"S Danese","year":"2022","unstructured":"Danese, S. et al. DOP42 efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active ulcerative colitis: 12-week results from the Phase 2 LATTICE-UC study. J. Crohn\u2019s Colitis 16, i091\u2013i092 (2022).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"1093_CR57","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jcph.1046","volume":"58","author":"C Banfield","year":"2018","unstructured":"Banfield, C. et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J. Clin. Pharmacol. 58, 434\u2013447 (2018).","journal-title":"J. Clin. Pharmacol."},{"key":"1093_CR58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/cts.12929","volume":"14","author":"RSP Singh","year":"2021","unstructured":"Singh, R. S. P. et al. Safety and pharmacokinetics of the oral TYK2 inhibitor PF-06826647: a phase I, randomized, double-blind, placebo-controlled, dose-escalation study. Clin. Transl. Sci. 14, 671\u2013682 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"1093_CR59","doi-asserted-by":"publisher","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","volume":"63","author":"BS Gerstenberger","year":"2020","unstructured":"Gerstenberger, B. S. et al. Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases. J. Med. Chem. 63, 13561\u201313577 (2020).","journal-title":"J. Med. Chem."},{"key":"1093_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","volume":"87","author":"C Tehlirian","year":"2022","unstructured":"Tehlirian, C. et al. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. J. Am. Acad. Dermatol. 87, 333\u2013342 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1093_CR61","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","volume":"140","author":"SB Forman","year":"2020","unstructured":"Forman, S. B. et al. TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial. J. Invest. Dermatol. 140, 2359\u20132370 e2355 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"1093_CR62","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.42519","volume":"75","author":"P Mease","year":"2023","unstructured":"Mease, P. et al. Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial. Arthritis Rheumatol. 75, 1370\u20131380 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1093_CR63","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","volume":"21","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn, W. J. et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin. Gastroenterol. Hepatol. 21, 2616\u20132628.e7 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1093_CR64","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","volume":"25","author":"Y Minegishi","year":"2006","unstructured":"Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745\u2013755 (2006).","journal-title":"Immunity"},{"key":"1093_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-250479","volume":"15","author":"O Ojuawo","year":"2022","unstructured":"Ojuawo, O., Allen, R., Hagan, G. & Piracha, S. Disseminated tuberculosis associated with deficient interleukin-23\/tyrosine kinase 2 signalling. BMJ Case Rep. 15, e250479 (2022).","journal-title":"BMJ Case Rep."},{"key":"1093_CR66","doi-asserted-by":"publisher","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","volume":"8","author":"CA Dendrou","year":"2016","unstructured":"Dendrou, C. A. et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci. Transl. Med. 8, 363ra149 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1093_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1010253","volume":"18","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. COVID-19 and systemic lupus erythematosus genetics: a balance between autoimmune disease risk and protection against infection. PLoS Genet. 18, e1010253 (2022).","journal-title":"PLoS Genet."},{"key":"1093_CR68","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).","journal-title":"Science"},{"key":"1093_CR69","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"M Nogueira","year":"2020","unstructured":"Nogueira, M., Puig, L. & Torres, T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs 80, 341\u2013352 (2020).","journal-title":"Drugs"},{"key":"1093_CR70","doi-asserted-by":"publisher","unstructured":"Fleischmann, R. et al. Safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor: as assessed by laboratory parameters \u2014 results from a phase 2 trial in psoriatic arthritis and 2 phase 3 trials in psoriasis. Arthritis Rheumatol. 74 https:\/\/doi.org\/10.1002\/art.42355 (2022).","DOI":"10.1002\/art.42355"},{"key":"1093_CR71","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cts.13435","volume":"16","author":"IM Catlett","year":"2023","unstructured":"Catlett, I. M. et al. First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin. Transl. Sci. 16, 151\u2013164 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"1093_CR72","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/art.24537","volume":"61","author":"AE Hak","year":"2009","unstructured":"Hak, A. E., Karlson, E. W., Feskanich, D., Stampfer, M. J. & Costenbader, K. H. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses\u2019 health study. Arthritis Rheumatol. 61, 1396\u20131402 (2009).","journal-title":"Arthritis Rheumatol."},{"key":"1093_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000464","volume":"8","author":"R Tummala","year":"2021","unstructured":"Tummala, R. et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci. Med. 8, e000464 (2021).","journal-title":"Lupus Sci. Med."},{"key":"1093_CR74","doi-asserted-by":"crossref","unstructured":"Fleischmann, R. et al. Safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor: as assessed by laboratory parameters \u2014 results from a phase 2 trial in psoriatic arthritis and 2 phase 3 trials in psoriasis. Arthritis Rheumatol. 74 (2022).","DOI":"10.1136\/annrheumdis-2022-eular.1862"},{"key":"1093_CR75","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/art.42526","volume":"75","author":"MM Tabata","year":"2023","unstructured":"Tabata, M. M. et al. The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis. Arthritis Rheumatol. 75, 1842\u20131849 (2023).","journal-title":"Arthritis Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01093-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01093-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:06:07Z","timestamp":1711533967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01093-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1038\/s41584-024-01093-w","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"9 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.F. declares that he has acted as a consultant for AbbVie, Amgen, Atomwise, BMS, Galvani, Galapagos, Gilead, GSK, Immunovant, Janssen, Eli Lilly. Novartis, Pfizer, UCB and Vyne; serves on the data safety monitoring boards for Celltrion, EMDSerano and Kiniksa; and has received clinical trial grants from AbbVie, Arthrosi, Biogen, BMS, Eli Lilly, Flexion, Galvani, Genentech, Gilead, GSK, Horizon, Janssen, Novartis, Oletec, Priovant, Scipher, Selecta, UCB and Viela. Y.T. declares that he has received speaking fees and\/or honoraria from AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Gilead, GlaxoSmithKline, Mitsubishi-Tanabe and Pfizer; and research grants from Asahi-Kasei, AbbVie, Behringer-Ingelheim, Chugai, Daiichi-Sankyo, Eisai and Takeda. D.G. declares that she has received grant support from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB; and consulting fees from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. E.M. declares that he has received research grants from AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, GSK, Janssen, Takeda and UCB; and advisory and\/or honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, GSK, Gilead, Novartis, Takeda and Zenas. J.F.M. declares that he has acted as a consultant for AbbVie, Biogen, Celgene, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer and UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}